Researchers at Stanford have developed practical applications that use germline information (e.g., germline epitope burden) for diagnosis, monitoring and treatment of cancer.
Researchers at Stanford University's Curtis Laboratory have used gene expression to categorize the sensitivity and resistance of anthracycline chemotherapy in breast cancer patients with utmost precision.
Researchers at Stanford have developed a method using expressed genetic barcodes to enable simultaneous lineage tracing and single cell profiling. Intratumor heterogeneity fosters tumor evolution which is a key contributor to therapeutic failure and the lethality of cancer.
Researchers at Stanford have leveraged spatial proteomic analysis to identify biomarkers with immediate implications for HER2-positive breast cancer treatment decision making and patient stratification.
Researchers at Stanford have developed methods of diagnosing and treating colorectal cancer based on the discovery of genetic aberrations indicative of a patient's risk of metastasis.
Stanford researchers have formulated a statistical model to determine the risk of breast cancer recurrence with unprecedented accuracy in women 5 – 20 years after initial diagnosis.